AbCellera Biologics Inc. (ABCL)
 NASDAQ: ABCL · Real-Time Price · USD
 5.36
 -0.26 (-4.63%)
  At close: Oct 30, 2025, 4:00 PM EDT
5.39
 +0.03 (0.56%)
  After-hours: Oct 30, 2025, 7:19 PM EDT
AbCellera Biologics Revenue
AbCellera Biologics had revenue of $17.08M in the quarter ending June 30, 2025, with 133.29% growth. This brings the company's revenue in the last twelve months to $32.88M, down -0.54% year-over-year. In the year 2024, AbCellera Biologics had annual revenue of $28.83M, down -24.17%.
Revenue (ttm) 
 $32.88M
Revenue Growth 
 -0.54%
P/S Ratio 
 48.38
Revenue / Employee 
 $55,161
Employees 
 596
Market Cap 
1.60B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 28.83M | -9.19M | -24.17% | 
| Dec 31, 2023 | 38.03M | -447.40M | -92.17% | 
| Dec 31, 2022 | 485.42M | 110.22M | 29.38% | 
| Dec 31, 2021 | 375.20M | 142.05M | 60.92% | 
| Dec 31, 2020 | 233.16M | 221.54M | 1,907.88% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| UnitedHealth Group | 435.16B | 
| Johnson & Johnson | 92.15B | 
| Merck & Co. | 64.24B | 
| Eli Lilly and Company | 59.42B | 
| AbbVie | 58.33B | 
| AstraZeneca | 56.50B | 
| Novartis AG | 56.37B | 
| Novo Nordisk | 49.11B | 
ABCL News
- 23 days ago - AbCellera to Participate at Upcoming Investor Conferences in November and December 2025 - Business Wire
- 24 days ago - AbCellera Biologics: Entering Growth Phase After A Pause - Seeking Alpha
- 4 weeks ago - AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025 - Business Wire
- 7 weeks ago - AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer - Business Wire
- 2 months ago - AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575 - Business Wire
- 2 months ago - AbCellera to Participate at Upcoming Investor Conferences in September - Business Wire
- 2 months ago - AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms - Business Wire